Maïga, M.Y., Traoré, H.A., Dembélé, M., et al. (1996) Ascites Liquid Infection in Internal Service of Medicine at the National Hospital of Pont G. Médecine et Chirurgie Digestives, 25, 219-222.

has been cited by the following article:

• TITLE: Effectiveness and Tolerance of Tenofovir Disoproxil Fumarate in Sub-Saharan Viral B Cirrhotic Patients

  AUTHORS: Doumbia K. Wife Samaké, Sow H. Wife Coulibaly, M. Y. Dicko, A. M. Diallo, Sanogo S. D. Wife Sidibe, A. Kondé, M. C. Tounkara, D. Sangare, A. Konaté, M. T. Diarra, M. Y. Maïga

  KEYWORDS: Cirrhosis, Tenofovir, HBV

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.9 No.2, February 28, 2019

  ABSTRACT: Tenofovir reduces viral load during viral cirrhosis B and improves prognosis. The aim of this study was to evaluate the effectiveness and safety of Tenofovir during the treatment of viral B cirrhosis. The study was retrospective and prospective on patients with viral B cirrhosis treated with Tenofovir in the Hepato-Gastroenterology Department of University Hospital Gabriel Touré in Bamako (Mali) and evaluated between three and six months after the start of treatment. We included 89 patients. The mean age was 44.5 ± 16 years with extremes of 18 and 90 years. The sex ratio was 1.2. At inclusion all patients had a detectable viral load with an average of 2651.96 ± 1495.85 IU/ml. Follow-up viral load was undetectable in 84.3% with patients between 3 and 6 months of treatment. The average detectable viral load was only 27.04 ± 21.05 IU/ml. There was also an improvement in hepatocellular function and few side effects. Conclusion: This study shows the interest of Tenofovir in the treatment of viral cirrhosis B with very few adverse effects.